Publication Name	World Journal of Pharmacology
Manuscript ID	21476
Country	Italy

Received	2015-07-15 09:13
Peer-Review Started	2015-07-15 12:06
To Make the First Decision	2015-09-28 11:28
Return for Revision	2015-09-28 20:41
Revised	2015-10-08 17:42
Second Decision	2015-11-04 18:06
Accepted by Journal Editor-in-Chief	2015-11-04 23:10
Accepted by Company Editor-in-Chief	2015-11-17 08:39
Articles in Press	2015-11-17 08:39
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2015-12-04 11:03
Publish the Manuscript Online	2015-12-08 16:45

ISSN	2220-3192 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Minireviews
Article Title	Quinolone-based first, second and third-line therapies for Helicobacter pylori
Manuscript Source	Invited Manuscript
All Author List	Enzo Ierardi, Giuseppe Losurdo, Floriana Giorgio, Andrea Iannone, Mariabeatrice Principi and Alfredo Di Leo
Funding Agency and Grant Number
Corresponding Author	Enzo Ierardi, Professor, Gastroenterology Section, Department of Emergency and Organ Transplantation, University of Bari, Piazza G. Cesare 11, 70124 Bari, Italy. e.ierardi@virgilio.it
Key Words	Helicobacter pylori; Eradication regimens; Fluoroquinolones; Antibiotic resistance; Levofloxacin; Rescue treatments
Core Tip	In the present minireview, we analyzed current evidence about the use of fluoroquinolones in first, second and third-line eradication regimens for Helicobacter pylori (H. pylori). The increasing resistances to levofloxacin are a worrying issue, that confirm the need to use this drug with proper care. We analyzed the current use of fluoroquinolones in first-line and rescue regimens, underlining possible pitfalls and mistakes that could be avoided in clinical practice. Novel molecules have been investigated, that could offer an interesting tool to combat H. pylori.
Publish Date	2015-12-08 16:45
Citation	Ierardi E, Losurdo G, Giorgio F, Iannone A, Principi M, Di Leo A. Quinolone-based first, second and third-line therapies for Helicobacter pylori. World J Pharmacol 2015; 4(4): 274-280
URL	http://www.wjgnet.com/2220-3192/full/v4/i4/274.htm
DOI	http://dx.doi.org/10.5497/wjp.v4.i4.274

Full Article (PDF)	WJP-4-274.pdf
Full Article (Word)	WJP-4-274.doc
Manuscript File	21476-Review.doc
Answering Reviewers	21476-Answering reviewers.pdf
Audio Core Tip	21476-Audio core tip.mp3
Conflict-of-Interest Disclosure Form	21476-Conflict-of-interest statement.pdf
Copyright License Agreement	21476-Copyright assignment.pdf
Non-Native Speakers of English Editing Certificate	21476-Language certificate.pdf
Peer-review Report	21476-Peer-review(s).pdf
Journal Editor-in-Chief Review Report	21476-Journal editor-in-chief review report.pdf
Scientific Misconduct Check	21476-Scientific misconduct check.pdf
Scientific Editor Work List	21476-Scientific editor work list.pdf